文献速递临床试验与 GCP

开喉剑喷雾剂(儿童型)治疗儿童急性咽炎和扁桃体炎所致咽痛的即时镇痛疗效与安全性评价:随机对照试验研究方案

Evaluation on immediate analgesic efficacy and safety of Kai-Hou-Jian spray (children's type) in treating sore throat caused by acute pharyngitis and tonsillitis in children: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-03-18

本研究为前瞻性、多中心、随机、双盲、平行组、安慰剂对照试验,计划纳入240例来自中国7个研究中心的急性咽炎/扁桃体炎患儿,随机分配至开喉剑喷雾剂(儿童型)组或安慰剂喷雾组,连续治疗5天。主要结局为镇痛起效时间,次要结局包括镇痛持续时间、0-3小时WBS评分时间曲线下面积等,主要安全性结局为不良事件发生率。该试验旨在评估开喉剑喷雾剂对儿童急性咽炎/扁桃体炎所致咽痛的即时镇痛疗效与安全性。

要点

  • 首个多中心随机双盲安慰剂对照试验探索中药喷雾剂对儿童急性咽痛即时镇痛效果。
  • 主要结局为镇痛起效时间,次要结局包括镇痛持续时间及WBS评分曲线下面积。
  • 计划纳入240例患儿,来自中国7个研究中心,连续治疗5天。

核心结论

  • 该试验旨在评估开喉剑喷雾剂(儿童型)对儿童急性咽炎/扁桃体炎所致咽痛的即时镇痛疗效与安全性。
  • 若结果阳性,可能为中药治疗儿童急性咽痛提供证据。

研究设计与样本

  • 前瞻性、多中心、随机、双盲、平行组、安慰剂对照试验。
  • 计划纳入240例来自中国7个研究中心的急性咽炎/扁桃体炎患儿。
  • 参与者随机分配至开喉剑喷雾剂组或安慰剂喷雾组,连续治疗5天。

关键数值与推荐

  • 主要结局为镇痛起效时间。
  • 次要结局包括镇痛持续时间、0-3小时WBS评分时间曲线下面积(AUC0-3 h)、镇痛起效率、咽痛消失率、WBS评分变化(按天)、咽部体征有效率及中医证候有效率。
  • 主要安全性结局为试验期间不良事件发生率,同时监测用药前后生命体征和实验室检查。

临床怎么用

  • 若试验证实有效且安全,开喉剑喷雾剂(儿童型)可能成为儿童急性咽炎/扁桃体炎所致咽痛的即时镇痛选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute pharyngitis and tonsillitis are common respiratory diseases for which children seek medical care. Their main clinical manifestation is sore throat which interferes with patients' quality of life. However, there is no proven effective or safe method to treat it. It is necessary to find an excellent strategy to reduce sore throat and reduce the burden of acute illness. We designed the randomized controlled trial with the characteristics of traditional Chinese medicine (TCM) to determine the clinical positioning of Kai-Hou-Jian spray (children's type) (KHJS) through evidence-based research. This trial aims to evaluate the immediate analgesic efficacy of KHJS on sore throat caused by acute pharyngitis and tonsillitis (wind-heat syndrome/heat exuberance in lung and stomach syndrome) in children and to observe its safety. METHODS/DESIGN: This is a prospective, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. It will include 240 children with acute pharyngitis/tonsillitis from 7 study sites across China. All participants are randomly assigned to two parallel treatment groups, one with KHJS and the other with placebo sprays, for 5 consecutive days. The primary outcome is the time of analgesic onset. Secondary outcomes include duration of analgesic effect, area under time curve of 0-3 h Wong-Baker FACES Pain Rating Scale (WBS) score (AUC0-3 h), rate of analgesic onset, rate of disappearance of sore throat, changes of WBS score (in days), effective rate of pharyngeal signs, and effective rate of TCM syndrome. The incidence of adverse events during the trial is the primary safety outcome. In addition, vital signs and laboratory tests before and after medication are monitored. DISCUSSION: To our knowledge, this will be the first clinical trial to explore the immediate analgesic efficacy of a Chinese patent medicine spray for acute pharyngitis/tonsillitis induced sore throat in children in a multicenter, randomized, double-blinded, parallel-group, placebo-controlled manner. Not only might it prove the efficacy and safety of KHJS in the treatment of sore throat caused by acute pharyngitis/tonsillitis in children, but it might also provide evidence for the treatment of acute sore throat with Chinese herbal medicine. TRIAL REGISTRATION: A multicenter, randomized, double-blind, very low-dose, parallel controlled trial for the immediate analgesic effect and safety of Kai-Hou- Jian spray (children's type) in the treatment of sore throat caused by acute pharyngitis and tonsillitis in children. Chinese Clinical Trial Registry ChiCTR2000031599 . Registered on 5 April 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ma YN, Zhong CL, Hu SY, et al. Evaluation on immediate analgesic efficacy and safety of Kai-Hou-Jian spray (children's type) in treating sore throat caused by acute pharyngitis and tonsillitis in children: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33736674. doi:10.1186/s13063-021-05148-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。